DOI: 10.1093/ibd/izad165 ISSN:

1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti
  • Gastroenterology
  • Immunology and Allergy

In this retrospective cohort study, tofacitinib was associated with higher adjusted odds of steroid-free clinical remission at 52 weeks and endoscopic remission within 52 weeks compared with vedolizumab. Adverse events were consistent with the known safety profiles of these agents.

More from our Archive